ReviewCureus2025
Revisiting the Role of Tolvaptan in the Management of Hyponatraemia in Acute Heart Failure: Balancing Quality of Life and Cost With Tolvaptan Treatment.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyponatraemia is a poor prognostic index in heart failure. It is a common complication of heart failure, associated with poorer outcomes including prolonged hospitalisation, increased morbidity, and reduced quality of life. For patients who have already developed this complication, the focus should be on improving their quality of life. The conventional management of hyponatraemia in heart failure largely depends on the cause and usually involves the intensification of the anti-heart failure regimen. For patients with severe hyponatraemia, it could mean an extra week's stay in the hospital on average or even longer, resulting in an increased rate of complications associated with prolonged hospitalisation. This not only increases healthcare costs but also exposes patients, particularly older adults, to risks related to immobility and hospital-acquired infections. In theory, tolvaptan could bridge this gap in selected patients to reduce hospitalisation and improve quality of life. Tolvaptan is a selective vasopressin V2 receptor antagonist. Arginine vasopressin (AVP) plays a significant role in the pathophysiology of heart failure. It inhibits the action of AVP on renal collecting ducts, promoting free water excretion. Tolvaptan increases serum sodium and reduces diuretic doses. While it has not been associated with increased mortality, evidence on morbidity and long-term outcomes remains inconsistent. In addition, high cost and safety concerns restrict its widespread use. This review highlights the role of tolvaptan beyond biochemical correction, with a focus on its potential to improve quality of life, reduce hospitalisations, and provide cost-effective benefits in carefully selected heart failure patients with hyponatraemia. By addressing these broader clinical and economic considerations, we provide a more balanced framework for evaluating its place in therapy. Nonetheless, further large, randomised controlled trials are required to confirm its long-term safety, cost-effectiveness, and overall impact on outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.